The role of microneedles for drug and vaccine delivery

Helen L. Quinn, Mary-Carmel Kearney, Aaron J. Courtenay, Maeliosa T. C. McCrudden, Ryan F. Donnelly

Research output: Contribution to journalReview article

67 Citations (Scopus)

Abstract

Introduction: Transdermal drug delivery offers a number of advantages for the patient, not only due to its non-invasive and convenient nature, but also due to factors such as avoidance of first-pass metabolism and prevention of gastrointestinal degradation. It has been demonstrated that microneedles (MNs) can increase the number of compounds amenable to transdermal delivery by penetrating the skin’s protective barrier, the stratum corneum, and creating a pathway for drug permeation to the dermal tissue below.

Areas covered: MNs have been extensively investigated for drug and vaccine delivery. The different types of MN arrays and their delivery capabilities are discussed in terms of drugs, including biopharmaceutics and vaccines. Patient usage and effects on the skin are also considered.

Expert opinion: MN research and development is now at the stage where commercialisation is a viable possibility. There are a number of long-term safety questions relating to patient usage which will need to be addressed moving forward. Regulatory guidance is awaited to direct the scale-up of the manufacturing process alongside provision of clearer patient instruction for safe and effective use of MN devices.
LanguageEnglish
Pages1769-1780
Number of pages11
JournalExpert Opinion on Drug Delivery
Volume11
Issue number11
DOIs
Publication statusE-pub ahead of print - 14 Jul 2014

Keywords

  • drug delivery
  • microneedle
  • skin
  • transdermal
  • vaccine

Cite this

Quinn, H. L., Kearney, M-C., Courtenay, A. J., McCrudden, M. T. C., & Donnelly, R. F. (2014). The role of microneedles for drug and vaccine delivery. Expert Opinion on Drug Delivery, 11(11), 1769-1780. https://doi.org/10.1517/17425247.2014.938635
Quinn, Helen L. ; Kearney, Mary-Carmel ; Courtenay, Aaron J. ; McCrudden, Maeliosa T. C. ; Donnelly, Ryan F. / The role of microneedles for drug and vaccine delivery. In: Expert Opinion on Drug Delivery. 2014 ; Vol. 11, No. 11. pp. 1769-1780.
@article{05749d7282d446cdab0328e59f16bfd1,
title = "The role of microneedles for drug and vaccine delivery",
abstract = "Introduction: Transdermal drug delivery offers a number of advantages for the patient, not only due to its non-invasive and convenient nature, but also due to factors such as avoidance of first-pass metabolism and prevention of gastrointestinal degradation. It has been demonstrated that microneedles (MNs) can increase the number of compounds amenable to transdermal delivery by penetrating the skin’s protective barrier, the stratum corneum, and creating a pathway for drug permeation to the dermal tissue below.Areas covered: MNs have been extensively investigated for drug and vaccine delivery. The different types of MN arrays and their delivery capabilities are discussed in terms of drugs, including biopharmaceutics and vaccines. Patient usage and effects on the skin are also considered.Expert opinion: MN research and development is now at the stage where commercialisation is a viable possibility. There are a number of long-term safety questions relating to patient usage which will need to be addressed moving forward. Regulatory guidance is awaited to direct the scale-up of the manufacturing process alongside provision of clearer patient instruction for safe and effective use of MN devices.",
keywords = "drug delivery, microneedle, skin, transdermal, vaccine",
author = "Quinn, {Helen L.} and Mary-Carmel Kearney and Courtenay, {Aaron J.} and McCrudden, {Maeliosa T. C.} and Donnelly, {Ryan F.}",
year = "2014",
month = "7",
day = "14",
doi = "10.1517/17425247.2014.938635",
language = "English",
volume = "11",
pages = "1769--1780",
journal = "Expert Opinion on Drug Delivery",
issn = "1742-5247",
number = "11",

}

Quinn, HL, Kearney, M-C, Courtenay, AJ, McCrudden, MTC & Donnelly, RF 2014, 'The role of microneedles for drug and vaccine delivery', Expert Opinion on Drug Delivery, vol. 11, no. 11, pp. 1769-1780. https://doi.org/10.1517/17425247.2014.938635

The role of microneedles for drug and vaccine delivery. / Quinn, Helen L.; Kearney, Mary-Carmel; Courtenay, Aaron J.; McCrudden, Maeliosa T. C.; Donnelly, Ryan F.

In: Expert Opinion on Drug Delivery, Vol. 11, No. 11, 14.07.2014, p. 1769-1780.

Research output: Contribution to journalReview article

TY - JOUR

T1 - The role of microneedles for drug and vaccine delivery

AU - Quinn, Helen L.

AU - Kearney, Mary-Carmel

AU - Courtenay, Aaron J.

AU - McCrudden, Maeliosa T. C.

AU - Donnelly, Ryan F.

PY - 2014/7/14

Y1 - 2014/7/14

N2 - Introduction: Transdermal drug delivery offers a number of advantages for the patient, not only due to its non-invasive and convenient nature, but also due to factors such as avoidance of first-pass metabolism and prevention of gastrointestinal degradation. It has been demonstrated that microneedles (MNs) can increase the number of compounds amenable to transdermal delivery by penetrating the skin’s protective barrier, the stratum corneum, and creating a pathway for drug permeation to the dermal tissue below.Areas covered: MNs have been extensively investigated for drug and vaccine delivery. The different types of MN arrays and their delivery capabilities are discussed in terms of drugs, including biopharmaceutics and vaccines. Patient usage and effects on the skin are also considered.Expert opinion: MN research and development is now at the stage where commercialisation is a viable possibility. There are a number of long-term safety questions relating to patient usage which will need to be addressed moving forward. Regulatory guidance is awaited to direct the scale-up of the manufacturing process alongside provision of clearer patient instruction for safe and effective use of MN devices.

AB - Introduction: Transdermal drug delivery offers a number of advantages for the patient, not only due to its non-invasive and convenient nature, but also due to factors such as avoidance of first-pass metabolism and prevention of gastrointestinal degradation. It has been demonstrated that microneedles (MNs) can increase the number of compounds amenable to transdermal delivery by penetrating the skin’s protective barrier, the stratum corneum, and creating a pathway for drug permeation to the dermal tissue below.Areas covered: MNs have been extensively investigated for drug and vaccine delivery. The different types of MN arrays and their delivery capabilities are discussed in terms of drugs, including biopharmaceutics and vaccines. Patient usage and effects on the skin are also considered.Expert opinion: MN research and development is now at the stage where commercialisation is a viable possibility. There are a number of long-term safety questions relating to patient usage which will need to be addressed moving forward. Regulatory guidance is awaited to direct the scale-up of the manufacturing process alongside provision of clearer patient instruction for safe and effective use of MN devices.

KW - drug delivery

KW - microneedle

KW - skin

KW - transdermal

KW - vaccine

U2 - 10.1517/17425247.2014.938635

DO - 10.1517/17425247.2014.938635

M3 - Review article

VL - 11

SP - 1769

EP - 1780

JO - Expert Opinion on Drug Delivery

T2 - Expert Opinion on Drug Delivery

JF - Expert Opinion on Drug Delivery

SN - 1742-5247

IS - 11

ER -